Search

Your search keyword '"Bonotto M"' showing total 220 results

Search Constraints

Start Over You searched for: Author "Bonotto M" Remove constraint Author: "Bonotto M"
220 results on '"Bonotto M"'

Search Results

3. T-DM1 versus pertuzumab, trastuzumab and a taxane as first-line therapy of early-relapsed HER2-positive metastatic breast cancer: an Italian multicenter observational study

4. The new vessel complex for the RFX-mod2 experiment: An effective synergy between fusion research and technological development

7. 261P Liquid biopsy–based biomarkers for the characterization of hormone receptor-positive (HR+) HER2-Low metastatic breast cancer (mBC)

8. 226P Exploring the impact of first-line therapies on the metastatic behavior of luminal-like metastatic breast cancer (mBC)

9. 249P A retrospective analysis on capecitabine and vinorelbine combination in metastatic breast cancer: The MARCELLINO study

10. 416P Prognostic impact of liquid biopsy (LB) biomarkers at relapse on second-line (2L) treatment (Tx) after progression to endocrine therapy (ET) in metastatic breast cancer (mBC): Ancillary analysis of the MAGNETIC.1 study

13. DIII-D research advancing the physics basis for optimizing the tokamak approach to fusion energy

14. Modeling the Prognostic Impact of Circulating Tumor Cells Enumeration in Metastatic Breast Cancer for Clinical Trial Design Simulation

15. Plasma physics and control studies planned in JT-60SA for ITER and DEMO operations and risk mitigation

16. DIII-D research advancing the physics basis for optimizing the tokamak approach to fusion energy

17. DIII-D research advancing the physics basis for optimizing the tokamak approach to fusion energy

19. DIII-D research advancing the physics basis for optimizing the tokamak approach to fusion energy

20. Plasma physics and control studies planned in JT-60SA for ITER and DEMO operations and risk mitigation

22. Completion of JT-60SA construction and contribution to ITER

28. 261P Survival outcomes of triple-negative breast cancer (TNBC) patients in the pre-immunotherapy age: An analysis of Gruppo Italiano Mammella (GIM) 14 BIOMETA study with a focus on biological subtypes

29. 252P Does the introduction of CDK4/6 inhibitors (CDKi) in first-line treatment of metastatic breast cancer (MBC) increase medical oncology workload?

30. 295P Clinical characterization and outcome of a HER2-low metastatic breast cancer (mBC) cohort receiving first-line treatment (1L) with ET +/- CDK 4/6 inhibitor (CDKi)

31. 294P Cell-free DNA (cfDNA) workflow for the risk definition of dose-limiting and recurrent neutropenia in patients treated with first-line endocrine therapy (ET) and cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) for metastatic breast cancer (MBC)

32. 293P Exploring the interplay between tumor burden and liquid biopsy longitudinal evaluation in hormone receptor-positive, HER2-negative metastatic breast cancer (MBC)

35. Status of the upgrade of RFX-mod2

36. 415P Patterns of time-to-progression intervals across clinical and liquid biopsy (LB) features in hormone receptor-positive (HR+) HER2-negative (HER2-) metastatic breast cancer (MBC) patients (pts) treated with first-line endocrine therapy (ET)

38. Lactate dehydrogenase as a prognostic biomarker in patients with hormone receptor-positive metastatic breast cancer treated with palbociclib: An exploratory cohort study

42. Modelling multi-modal Resistive Wall Mode feedback control in JT-60SA perspective high beta scenarios

43. Advances in the physics studies for the JT-60SA tokamak exploitation and research plan

44. Drug holidays and overall survival in patients treated for metastatic colorectal cancer

45. Clinical decision making and multidisciplinary team meetings (MDMs) in early breast cancer. Is the agreement between planned and applied therapeutic program?

46. The role of sidedness in second-line therapy for RAS wild-type colorectal cancer: a network meta-analysis (NMA)

47. Erratum to: Breakthrough pain and its treatment: critical review and recommendations of IOPS (Italian Oncologic Pain Survey) expert group

48. Neutrophil-to-lymphocyte and lymphocyte-to-monocyte ratios in breast cancer

49. A risk score integrating lymphocytes ratios (LRs) and lactate dehydrogenase (LDH) levels to predict prognosis in metastatic breast cancer (MBC) patients

50. The SENECA study: Prognostic role of serum biomarkers in elderly metastatic colorectal cancer patients

Catalog

Books, media, physical & digital resources